APTOF · As filed with the SEC
Aptose Biosciences cash flow statement, by quarter
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 | Q2 2024† 3 months ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net Income | (7,634,000) | — | — | — | (5,543,000) | — | (6,953,000) | (7,252,000) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||||||||
| Stock-based compensation | 129,000 | — | — | — | 326,000 | — | (13,000) | 207,000 |
| Depreciation and amortization | — | — | — | — | — | — | 4,000 | 8,000 |
| Depreciation of property and equipment | 2,000 | — | — | — | 3,000 | — | — | — |
| Loss on disposal of property and equipment | — | — | — | — | 0 | — | 0 | 66,000 |
| Amortization of right-of-use assets | — | — | — | — | 96,000 | — | 92,000 | 94,000 |
| Interest on lease liabilities | — | — | — | — | — | — | 15,000 | 18,000 |
| Noncash operating lease expense | 104,000 | — | — | — | — | — | — | — |
| Interest on lease liabilities | 3,000 | — | — | — | 13,000 | — | — | — |
| Interest on loan payable to related party | 433,000 | — | — | — | 145,000 | — | — | — |
| Unrealized gain on short-term investment | 0 | — | — | — | (2,000) | — | 0 | 1,000 |
| Accrued interest on investments | — | — | — | — | — | — | 0 | (9,000) |
| Deferred financing expenses | — | — | — | — | — | — | — | 0 |
| Accrued interest on investments | — | — | — | — | 0 | — | — | — |
| Change in operating assets and liabilities: | ||||||||
| Prepaid expenses | 364,000 | — | — | — | 301,000 | — | 324,000 | 560,000 |
| Other assets | (1,172,000) | — | — | — | 296,000 | — | (768,000) | 81,000 |
| Operating lease payments | — | — | — | — | (113,000) | — | (112,000) | (119,000) |
| Change in operating lease liability | (116,000) | — | — | — | — | — | — | — |
| Accounts payable, related party | — | — | — | — | 0 | — | 0 | 0 |
| Accounts payable | — | — | — | — | — | — | (5,281,000) | 4,690,000 |
| Accounts payable | — | — | — | — | 1,132,000 | — | — | — |
| Accounts payable | 899,000 | — | — | — | — | — | — | — |
| Accrued liabilities | 1,147,000 | — | — | — | 551,000 | — | 2,316,000 | (4,123,000) |
| Cash used in operating activities | (5,841,000) | — | — | — | (2,795,000) | — | (10,376,000) | (5,778,000) |
| Cash flows from investing activities: | ||||||||
| Disposal/(purchase) of property and equipment, net | — | — | — | — | — | — | 0 | 17,000 |
| (Acquisition) maturity of investments, net | — | — | — | — | 0 | — | 0 | 1,992,000 |
| Disposal of property and equipment | — | 0† | 0† | 0† | 0 | 5,000† | 0† | 17,000† |
| Cash provided by investing activities | 0 | — | — | — | 0 | — | 0 | 2,009,000 |
| Cash flows from financing activities: | ||||||||
| Proceeds from loan payable with related party | 5,850,000 | — | — | — | — | — | 10,000,000 | — |
| Issuances of common shares and warrants under the Registered Direct Offering | — | — | — | — | — | — | 0 | 4,140,000 |
| Issuance of common shares and warrants under the S-1 Filing | — | — | — | — | — | — | 0 | 0 |
| Shares issuances to Hanmi under subscription agreement | — | — | — | — | — | — | 0 | 0 |
| Repayment of loan with related party | — | 0† | 0† | — | — | — | — | — |
| January 2024 Public Offering | — | — | — | — | 0 | — | — | — |
| Hanmi Private Placement | — | — | — | — | 0 | — | — | — |
| The 2023 CMPO | — | — | — | — | — | — | 0 | 694,000 |
| The 2022 ATM Offering | — | — | — | — | — | — | 0 | 97,000 |
| The 2023 CMPO | — | — | — | — | — | — | 0 | — |
| Cost of offering | — | — | — | — | — | — | 0 | (177,000) |
| The 2025 ATM Offering | 0 | — | — | — | 828,000 | — | — | — |
| ESPP | 0 | — | — | — | 1,000 | — | — | — |
| Cost of offering | — | — | — | — | — | — | 0† | — |
| Issuance of common shares under the ESPP plan | — | — | — | — | — | — | 8,000 | 0 |
| Cash provided by financing activities | 5,850,000 | — | — | — | 829,000 | — | 10,008,000 | 4,754,000 |
| Effect of exchange rate fluctuations on cash | 0 | — | — | — | 2,000 | — | 0 | (1,000) |
| Increase (decrease) in cash and restricted cash | 9,000 | — | — | — | (1,964,000) | — | (368,000) | 984,000 |
| Cash and restricted cash, beginning of period | 4,096,000 | 1,637,000 | 1,298,000 | 4,743,000 | 6,707,000 | 7,962,000 | 8,330,000 | 7,346,000 |
| Cash and restricted cash, end of period | 4,105,000 | 4,096,000 | 1,637,000 | 1,298,000 | 4,743,000 | 6,707,000 | 7,962,000 | 8,330,000 |
| Supplemental disclosures of non-cash financing activities: | ||||||||
| Conversion of loan payable with related party to common shares | 0 | — | — | — | — | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.